5.9 High-Level Pharmaceutical Development Financial Forecast - F

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V
1	*this summary provides a way to share high-level forecast of costs to reach major milestones. This should not replace a bottom-up, detailed budget build that is customized for your company operations
2
3
4	COMPANY NAME
5	Budget Forecast
6			Year 1				Year 2				Year 3				Year 4				Year 5
7		TOTAL	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q

8
9	Nonclinical	0
10	Chemistry	0
11	Primary Pharmacology	0
12	ADME / PK	0
13	in vitro Safety / Secondary Pharmacology	0
14	Animal POC and Exploratory Tox	0
15	IND-Enabling	0
16	CMC (DS/DP)	0
17	CMC (DS/DP)	0
18		0
19		0
20	Clinical + Regulatory	0
21	Phase 1a/b (# patients)	0
22	Phase 2a (# patients)	0
23		0
24		0
25	R&D Fixed	0
26	R&D Fixed	0
27	G&A	0
28	G&A	0
29	CapEx	0
30		0
31
32	Sub-totals	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
33	TOTAL to DC	0
34	TOTAL to P1b (Year)	0
35	TOTAL to P2a (Year)	0
36	TOTAL/YEAR	0				0				0				0				0				0
37
38
39			Assumtions:
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100